NRC Health
NRC Health is classed by the SEC under Services-Commercial Physical & Biological Research (industry code 8731), based in Lincoln, NE. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $137 million and a profit of $11 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a project business: prior from its industry code (SEC 8731, Services-Commercial Physical & Biological Research); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.2 out of ten, 9 of 9 metrics filed: past 5.7 out of ten, present 5.2 out of ten, future 4.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 4.6 out of ten. 1 warning event since 2017; the latest 2018-04-20. 46th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 5.3 out of ten. +2% a year over 9 filed years; profitable in 9 of 9. 53rd percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 8.1 out of ten. Share count shrank 3.7% a year. 100% of cash flow returned. Insiders: 0 sales, 1 purchases. 81st percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.2 out of ten. ROE 83%: 83¢ of profit per shareholder dollar. Leverage 90%: owes 90¢ per asset dollar. 62nd percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 5.7 out of ten. top 43% of 12 in its family; net margin 8.4%. 57th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 2.5 out of ten. bottom 25% of 8 in its family for leadership. 25th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 3.3 out of ten. bottom 33% of 12 in its family for room to expand. 33rd percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 6.3 out of ten. top 37% of 12 in its family for growth drivers. 63rd percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 4.1 out of ten. bottom 41% of 11 in its family for expectations against reality. 41st percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-05 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-04 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-28 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-08-13. Filings on record since 1997. Read from EDGAR 2026-10-12.
Who runs it
Hays, Michael D. (Chairman); Rau, Jason Russell (Executive Vice President); Harrison, Shane R (EVP & Chief Financial Officer); Hrdy, Helen (EVP & Chief Operating Officer); Freeman, Jordan Nicole (Chief Accounting Officer); Burik, David (EVP, Strategic Insights); Berwick, Donald M (director); Bhandari, Parul (director); Lockhart, Stephen H (director); Nunnelly, John N (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.